These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
342 related articles for article (PubMed ID: 27193678)
1. Reproducible pharmacogenomic profiling of cancer cell line panels. Haverty PM; Lin E; Tan J; Yu Y; Lam B; Lianoglou S; Neve RM; Martin S; Settleman J; Yauch RL; Bourgon R Nature; 2016 May; 533(7603):333-7. PubMed ID: 27193678 [TBL] [Abstract][Full Text] [Related]
2. Enhancing reproducibility in cancer drug screening: how do we move forward? Hatzis C; Bedard PL; Birkbak NJ; Beck AH; Aerts HJ; Stem DF; Shi L; Clarke R; Quackenbush J; Haibe-Kains B Cancer Res; 2014 Aug; 74(15):4016-23. PubMed ID: 25015668 [TBL] [Abstract][Full Text] [Related]
6. A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening. Gupta A; Gautam P; Wennerberg K; Aittokallio T Commun Biol; 2020 Jan; 3(1):42. PubMed ID: 31974521 [TBL] [Abstract][Full Text] [Related]
7. [Results of screening of antineoplastic agents: the eleventh report]. Gan To Kagaku Ryoho; 2007 Mar; 34 Suppl 1():1-111. PubMed ID: 17569278 [No Abstract] [Full Text] [Related]
8. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Barretina J; Caponigro G; Stransky N; Venkatesan K; Margolin AA; Kim S; Wilson CJ; Lehár J; Kryukov GV; Sonkin D; Reddy A; Liu M; Murray L; Berger MF; Monahan JE; Morais P; Meltzer J; Korejwa A; Jané-Valbuena J; Mapa FA; Thibault J; Bric-Furlong E; Raman P; Shipway A; Engels IH; Cheng J; Yu GK; Yu J; Aspesi P; de Silva M; Jagtap K; Jones MD; Wang L; Hatton C; Palescandolo E; Gupta S; Mahan S; Sougnez C; Onofrio RC; Liefeld T; MacConaill L; Winckler W; Reich M; Li N; Mesirov JP; Gabriel SB; Getz G; Ardlie K; Chan V; Myer VE; Weber BL; Porter J; Warmuth M; Finan P; Harris JL; Meyerson M; Golub TR; Morrissey MP; Sellers WR; Schlegel R; Garraway LA Nature; 2012 Mar; 483(7391):603-7. PubMed ID: 22460905 [TBL] [Abstract][Full Text] [Related]
9. Pathophysiologically relevant in vitro tumor models for drug screening. Das V; Bruzzese F; Konečný P; Iannelli F; Budillon A; Hajdúch M Drug Discov Today; 2015 Jul; 20(7):848-55. PubMed ID: 25908576 [TBL] [Abstract][Full Text] [Related]
10. Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets. Dempster JM; Pacini C; Pantel S; Behan FM; Green T; Krill-Burger J; Beaver CM; Younger ST; Zhivich V; Najgebauer H; Allen F; Gonçalves E; Shepherd R; Doench JG; Yusa K; Vazquez F; Parts L; Boehm JS; Golub TR; Hahn WC; Root DE; Garnett MJ; Tsherniak A; Iorio F Nat Commun; 2019 Dec; 10(1):5817. PubMed ID: 31862961 [TBL] [Abstract][Full Text] [Related]
11. More than fishing for a cure: The promises and pitfalls of high throughput cancer cell line screens. Ling A; Gruener RF; Fessler J; Huang RS Pharmacol Ther; 2018 Nov; 191():178-189. PubMed ID: 29953899 [TBL] [Abstract][Full Text] [Related]
12. Harnessing the power of human tumor-derived cell lines for the rational design of cancer therapies. Plaisier CL; Baliga NS Pigment Cell Melanoma Res; 2012 Jul; 25(4):406-8. PubMed ID: 22781216 [No Abstract] [Full Text] [Related]
13. Registered report: Systematic identification of genomic markers of drug sensitivity in cancer cells. Vanden Heuvel JP; Bullenkamp J; Elife; 2016 Jun; 5():. PubMed ID: 27336789 [TBL] [Abstract][Full Text] [Related]
14. JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs. Kong D; Yamori T Bioorg Med Chem; 2012 Mar; 20(6):1947-51. PubMed ID: 22336246 [TBL] [Abstract][Full Text] [Related]
15. Drug design and testing: profiling of antiproliferative agents for cancer therapy using a cell-based methyl-[3H]-thymidine incorporation assay. Griffiths M; Sundaram H Methods Mol Biol; 2011; 731():451-65. PubMed ID: 21516428 [TBL] [Abstract][Full Text] [Related]
16. Current Trends in Drug Sensitivity Prediction. Cortes-Ciriano I; Mervin LH; Bender A Curr Pharm Des; 2016; 22(46):6918-6927. PubMed ID: 27784247 [TBL] [Abstract][Full Text] [Related]
17. Overview: the art of cancer drug screening: molecular target versus milieu-based screens. Sawyers CL; Sausville EA Curr Opin Investig Drugs; 2002 Mar; 3(3):478-81. PubMed ID: 12054100 [No Abstract] [Full Text] [Related]
18. Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens. Larsson P; Engqvist H; Biermann J; Werner Rönnerman E; Forssell-Aronsson E; Kovács A; Karlsson P; Helou K; Parris TZ Sci Rep; 2020 Apr; 10(1):5798. PubMed ID: 32242081 [TBL] [Abstract][Full Text] [Related]